A mandate for an investor-owned biotech focused on the transformation of an academic research team into a clinical-stage development company and serious player in the fight against chronic hepatitis B virus infection. The mandate included the implementation of several strategic initiatives aimed at optimizing the workforce, streamlining development targets, and enhancing overall efficiency. It involved reconfiguring of existing collaborations and building of new alliances with industry partners particularly in China and the United States.